JACOB GLANVILLE, PHD
Former Chief Executive Officer
Former Chairman of the Board
With the acquisition of Distributed Bio by Charles River Laboratories, Jacob Glanville transitioned to function as CEO of our therapeutics spinout Centivax where he will focus on universal vaccines, therapeutic antibodies against Covid-19, and other infectious diseases.
Please visit www.centivax.com for more information.
Jacob Glanville is an entrepreneur, inventor and computational immuno-engineer. He developed the core business model, the research teams, and the technologies that enabled Distributed Bio to become profitable without investment. He has developed multiple seminal methods in the fields of high-throughput antibody repertoire sequencing (PNAS 2009), repertoire decoding algorithms (Nature 2017), single-cell TCR receptor & phenotype sequencing (Nature Biotech, 2014), deconstructing genetic variation in the adaptive immune system (Nature Communications 2015, Nature Reports 2016, PNAS 2011, TI 2017), and computationally guided antibody library engineering (JMB 2011, JMB 2013, COSB 2015) that have enabled Distributed Bio to deliver therapeutic lead antibodies to over 50 programs across the pharmaceutical industry.
He is a Stanford University Scientific Advisory Committee member for the Sean Parker Center for Allergy and Asthma Research, a Scientific Advisory Board member for the University of San Francisco's Biotechnology program, a repeat Gates Foundation/Stanford University Computational and Systems Immunology Grant Recipient while a PhD Candidate with Mark Davis at Stanford, a National Institute of Health Principal Investigator with an SBIR award for our universal antivenom program, a Gates Foundation Grand Challenge awardee for the Centivax universal vaccine program, a Recipient of Pfizer Achievement award 2010 while Principal Scientist at Pfizer, and has been a course-founding instructor and guest lecturer for multiple graduate-level applied computational and systems immunology courses at Stanford and USF.
As Co-Founder, CEO and President of Distributed Bio, he and his teams apply computationally-guided immunoengineering methods to enable a new generation of monoclonal antibody discovery and universal vaccine design. In addition to counting over 50 pharmaceutical companies and biotechnology startups as his Distributed Bio clients, he enjoys collaborating with multiple partners to generate exciting new technologies in biomedicine.